Background: Over 25 drugs have been approved for the treatment of HIV-1 replication. All but one of these drugs is delivered as an oral medication. Previous studies have demonstrated that two drugs, decitabine and gemcitabine, have potent anti-HIV-1 activities and can work together in synergy to reduce HIV-1 infectivity via lethal mutagenesis. For their current indications, decitabine and gemcitabine are delivered intravenously.

Methods: As an initial step towards the clinical translation of these drugs for the treatment of HIV-1 infection, we synthesized decitabine and gemcitabine prodrugs in order to increase drug permeability, which has generally been shown to correlate with increased bioavailability in vivo. In the present study we investigated the permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine prodrugs and selected the divalerate esters of each as candidates for further investigation.

Results: Our results provide the first demonstration of divalerate prodrugs of decitabine and gemcitabine that are readily permeable, stable and possess anti-HIV-1 activity.

Conclusions: These observations predict improved oral availability of decitabine and gemcitabine, and warrant further study of their ability to reduce HIV-1 infectivity in vivo.

Introduction

There are currently six classes of drugs approved to treat individuals infected with HIV-1. A combination of at least two to three classes of anti-HIV-1 drugs are typically used to suppress viral replication and decrease the emergence of drug-resistant virus. Despite the use of combination antiretroviral therapy, drug-resistant virus can emerge when active drug levels do not sufficiently suppress virus replication. Once drug resistance emerges, transmission of drug-resistant virus represents a significant public health issue. The presence and transmission of drug-resistant HIV-1 emphasizes the need for the development of novel anti-HIV-1 drugs that exploit new drug targets. One potential drug target that has yet to be exploited clinically is the mutation rate of HIV-1.

The high mutation rate of HIV-1 (3.4×10⁻⁵ mutations/base pair/replication cycle) [1] enables the virus to evade the immune system and to become resistant to drug therapy. However, this high mutation rate also leads to the production of a high proportion of non-infectious virus. Lethal mutagenesis is a strategy that uses chemotherapeutics to increase the mutation rate to the point where the virus is unable to replicate with enough fidelity to remain infectious [2,3].

We previously described the combination of two clinically approved nucleoside analogues, decitabine and gemcitabine, that appears to decrease viral infectivity by lethal mutagenesis in cell culture [4]. Decitabine is used clinically to treat myelodysplastic syndrome (MDS) [5], while gemcitabine is used to treat pancreatic, ovarian, lung and breast cancers [6]. Decitabine is used clinically for its ability to inhibit DNA methyltransferase activity, which alters DNA methylation and gene expression [7,8]. In contrast, gemcitabine inhibits ribonucleotide reductase, which reduces dNTP pools and can decrease cell proliferation [9–11].

We previously demonstrated that the combination of decitabine and gemcitabine inhibited viral replication...
Materials and methods

General chemistry methodologies
All commercial reagents (Sigma–Aldrich [St Louis, MO, USA], Acros [Geel, Belgium], Berry and Ajinomoto, USA) were well below those used clinically for the treatment of MDS and solid cancers, respectively. These data suggest that decitabine and gemcitabine could be repositioned as antiretroviral agents. However, due to poor bioavailability, decitabine and gemcitabine must be administered intravenously in order to achieve a plasma concentration high enough to treat their respective conditions. While it is possible that high doses of the drugs could be given orally multiple times per day in order to achieve a sustained antiviral effect, such a dosing regimen would likely lead to poor patient compliance which would facilitate the emergence of drug resistant virus. Thus, the low bioavailability of gemcitabine and decitabine limits their use as antiretroviral agents.

The low bioavailability of gemcitabine and decitabine has been attributed to low intestinal permeability, as well as their rapid deamination by cytidine deaminase, an enzyme that is highly expressed in the liver and intestines. Additionally, rapid phosphorylation of the 5′-hydroxyl group of gemcitabine in the liver tissues results in its accumulation in the liver and kidney thereby preventing its distribution in target tissues [16,17]. Several approaches have been used to improve the bioavailability and pharmacokinetic properties of decitabine and gemcitabine, including prodrugs [16–21]. Prodrug approaches have been used to increase intestinal permeability and to minimize phosphorylation and retention by the liver and kidneys [17]. In addition to prodrugs, tetrahydrouridine, an orally available inhibitor of cytidine deaminase, has been used to prevent deamination of decitabine and gemcitabine, which resulted in an increase in the bioavailability of decitabine [22] and an increase in the half-life of gemcitabine [23]. Despite the multiple approaches to improve the bioavailability and pharmacokinetic properties of decitabine and gemcitabine, prodrug derivatives of gemcitabine and decitabine limits their use as antiretroviral agents.

Here, we describe chemically stable and biologically active decitabine and gemcitabine prodrugs that demonstrate improved permeability in the Caco-2 model of oral availability compared to the parent drugs. Additionally, both prodrugs were stable at a wide pH range and retained biological activity. These observations predict improved oral availability of decitabine and gemcitabine and warrant further studies of these prodrugs in vivo.
neomycin. Caco-2 cells were cultured in DMEM with Glutamax, 10% FBS and supplemented with penicillin/streptomycin/fungizone and non-essential amino acids.

Caco-2 assay to assess permeability
The Caco-2 assay was performed by Cerep, Inc. (Seattle, WA, USA). Briefly, Caco-2 cells (passage 15) were cultured for 21–25 days to form a confluent monolayer on 96-well multiscreen plates. All samples were supplemented with basal medium containing 20% FCS, 10% FBS, penicillin/streptomycin/fungizone and non-essential amino acids. Solvents B and samples were analysed at 0 and 60 min by HPLC-MS/MS. In addition to the parent compounds, the expected metabolites of all compounds were also monitored including the valerate and parent forms of each prodrug as well as the ring-opened forms of decitabine [27,28]. After permeability of the parent compounds and prodrugs were assessed, the monolayer integrity was assessed using fluorescein. Cell monolayers that demonstrated a fluorescein permeability of less than $1.5 \times 10^{-6}$ cm/s were considered intact.

The permeability coefficient ($P_{app}$) was calculated from the following equation: $P_{app}$ (cm/s) = $V_R \times C_{\text{Rmid}} / \Delta t \times (1/A \times (C_{\text{Rmid}} - C_{\text{Bmid}}))$. Where $V_R$ is the volume of in the receiver chamber, $C_{\text{Rmid}}$ is the concentration of compound in the receiver chamber at the end of the time point, $\Delta t$ is the incubation time (60 min), and $A$ is the surface area of the cell monolayer. $C_{\text{Bmid}}$ is the calculated midpoint concentration of the compound in the donor chamber and $C_{\text{Rmid}}$ is the midpoint concentration of the test compound in the receiver chamber. Concentrations of the compounds were expressed as peak areas of the test compound.

Half-life calculation for decitabine and gemcitabine valerate prodrugs
Prodrugs (3–4 mg) were diluted into a mixture of 10 ml of ethanol, 10 ml of water and 10 ml of appropriate buffer solution. Aliquots were analysed by HPLC at different times.

For pH 2.0, both decitabine valerate and gemcitabine valerate were examined at the following time points: 0, 55, 109, 163 and 218 min. For half-life calculations of decitabine valerate at pH 4.65, 16 different time points were examined including: 0 h, 5 h, 10 h, 35 h and 45 h. To determine the half-life at pH 4.65, gemcitabine valerate and metabolites thereof were examined at 10 different time points between 0–30 h including 0, 5, 10, 24 and 29 h. For half-life determination at pH 7.4, decitabine valerate and gemcitabine valerate were examined at 16 different time points between 0 and 35 h, including 0, 5, 10, 24 and 35 h.

HPLC conditions
The HPLC conditions include solvent A composed of an aqueous solution of 0.01 M of ammonium formate, the pH of the solution adjusted to 4.5 with formic acid. Solvent B was acetonitrile. The flow rate was 5 ml/min. The following method was used: from 0 to 1 min, 0 to 10% B; from 1 to 6 min, 10% B; from 6 to 10 min, 10 to 100% B; from 10 to 20 min, 100% B; from 20 to 21 min, 100 to 0% B; from 21 to 23 min, 0% B. The observed retention time for decitabine valerate was 13.79 min and for gemcitabine valerate was 14.28 min.

Production of virus stocks
293T cells (1.3×10^6) were plated on 10 cm culture dishes 24 h before transfection. The cells were transfected by calcium phosphate co-precipitation with 15 μg of the envelope-deficient HIV vector and 1.5 μg of a plasmid encoding the HIV envelope, pNL4-3prov (obtained from Eric Freed, NIH, Frederick, MD, USA). The medium was replaced with 6 ml of DMEM containing 10% FCS serum and penicillin/streptomycin/fungizone. The pH of the solution was maintained to 4.5 with formic acid. Solvent B was acetonitrile. The flow rate was 5 ml/min. The following method was used: from 0 to 1 min, 0 to 10% B; from 1 to 6 min, 10% B; from 6 to 10 min, 10 to 100% B; from 10 to 20 min, 100% B; from 20 to 21 min, 100 to 0% B; from 21 to 23 min, 0% B. The observed retention time for decitabine valerate was 13.79 min and for gemcitabine valerate was 14.28 min.

Drug treatments and infection
U937-MAG1-CXCR4_CEM cells (6.2×10^5/well) were plated in a 12-well culture dish 24 h prior to prodrug treatment. Cells were treated with either prodrugs individually or in combination 2 h prior to infection. After the 2 h pretreatment, the viral stock (500 μl) was added to each well to give a final volume of 1 ml and a final drug concentration that is indicated in Figure 1. After infection (24 h), the medium was replaced. Cells were harvested for analysis by flow cytometry 48 h after infection.

Flow cytometry to assess anti-HIV effect of decitabine and gemcitabine valerate prodrugs
The envelope-deficient HIV-1 vector used to generate virus expresses green fluorescent protein (GFP). Therefore, flow cytometry can be used to detect the percentage of cells infected by quantifying the percentage of cells expressing GFP. To do this, forward and side scatter gating was used to eliminate non-viable cells. 10,000 cells were then analysed for fluorescence at 488 nm to detect GFP signal. A histogram was used to determine the percentage of cells expressing GFP.
Cellular proliferation assay
Cell proliferation was examined using the CellTiter-Glo kit from Promega (Madison, WI, USA) according to the manufacturer's instructions. U373-MAGI-CXCR4-CEM cells (4,500 cells/well) were plated in a 96-well dish 24 h prior to drug treatment. Cells were treated with the prodrugs individually or in combination for 24 h. After 24 h of exposure to the prodrugs, the media was changed and fresh media without prodrug was added. 24 h later (for a total of 48 h after drugs were added), proliferation was assessed as described in the manufacturer's instructions. Dimethyl sulfoxide (DMSO) was used as a control for the untreated cells. The data were converted to relative cell numbers by setting the value for untreated cells at 100 for each experiment and then multiplying the data for the other samples by the number used to convert the no-drug-treated cells to 100. This conversion was normalized for differences in luciferase activity among different experiments.

Statistical analyses
Data were analysed by calculating the mean ± standard deviation (SD). One-way analysis of variance (ANOVA) with Tukey’s post-test was used to assess differences among treatment groups. A P-value of <0.05 was considered statistically significant.
Results

Effect of decitabine divalerate and gemcitabine divalerate on permeability

Decitabine and gemcitabine have poor bioavailability [23] which renders oral administration of these drugs suboptimal [17]. Therefore, a successful prodrug approach should increase intestinal permeability and could make oral administration of these drugs practical. To examine the intestinal permeability of gemcitabine and gemcitabine prodrugs, we used the Caco-2 assay, a well-established in vitro system that models intestinal permeability and efflux liability of compounds [29]. Typical permeability values using the Caco-2 assay range from $5 \times 10^{-9}$ cm/s to $5 \times 10^{-5}$ cm/s. Permeabilities greater than $1 \times 10^{-6}$ cm/s are associated with well absorbed compounds whereas permeabilities of less than $1 \times 10^{-7}$ cm/s are associated with poor intestinal absorption [30]. A panel of 10 decitabine and gemcitabine prodrugs was examined for permeability using the Caco-2 assay. The divalerate prodrugs demonstrated the most improved permeability compared to the parent compounds (data not shown and Figure 2). Specifically, the results indicate that the permeability of decitabine divalerate and gemcitabine divalerate were significantly improved compared to the parent compounds (Table 1). Specifically, the permeability of decitabine divalerate was fourfold higher than the permeability of decitabine ($3.2 \times 10^{-6}$ cm/s versus $0.8 \times 10^{-6}$ cm/s). Similarly, the permeability of gemcitabine divalerate was 4.2-fold higher than the permeability of gemcitabine ($2.1 \times 10^{-6}$ cm/s versus $0.5 \times 10^{-6}$ cm/s). These permeability values predict that both decitabine divalerate and gemcitabine divalerate would be well absorbed. In contrast, the permeability values of decitabine and gemcitabine are typical of compounds that would be predicted to have low to moderate intestinal absorption.

Figure 2. Structure of gemcitabine, decitabine and the divalerate prodrugs
The half-life of decitabine divalerate and gemcitabine divalerate at pH 2.0, 4.65 and 7.4.

The results of the Caco-2 assay indicate that the decitabine and gemcitabine divalerate prodrugs have improved intestinal permeability. To examine if the prodrugs demonstrate sufficient stability, we examined the half-life of the prodrugs at pH 2.0, which is consistent with the pH of the stomach; pH 4.65, which is consistent with the pH of the duodenum near the pylorus; and pH 7.4, which is consistent with the pH of the plasma and near the pH of the terminal ileum [31,32]. Stability at pH greater than 7.4 was not examined as these prodrugs are expected to be absorbed in the gastrointestinal tract prior to reaching alkaline conditions. The estimated half-life of decitabine divalerate at pH 7.4 was 28 h (Table 2), a value that is significantly greater than 12.9 ±0.9 h reported for the parent compounds at the same pH [33]. The estimated half-life of decitabine divalerate was 17 h at pH 2.0 and 36 h at pH 4.65 (Table 2). These results indicate that decitabine divalerate is stable at a wide range of pH. The estimated half-life of gemcitabine divalerate at pH 7.4 was 135 h, which is similar to that reported for gemcitabine at pH 7.4 [34]. As expected, gemcitabine divalerate was stable at both pH 2.0 and pH 4.65, as demonstrated by a half-life of 85 h and 247 h, respectively.

Effect of decitabine divalerate and gemcitabine divalerate on HIV-1 infectivity and cell proliferation

The anti-HIV-1 activity of decitabine divalerate and gemcitabine divalerate was assessed using an assay that enables detection of infected cells through quantification of a GFP marker gene expressed in the HIV-1 vector used to generate virus. The assay, which we have previously described [4,26], uses an HIV-1 vector that expresses GFP, but does not express the HIV-1 envelope. Therefore, vector virus was made by transfecting 293T cells with both the HIV-1 vector plasmid DNA as well as a plasmid that encodes for the HIV-1 envelope. Virus made from 293T cells was then used to infect cells that are pretreated with solvent (DMSO) or one of the prodrugs. Infected cells are detected as GFP-expressing cells by flow cytometry. As shown in Figure 1, treatment with either gemcitabine divalerate or decitabine divalerate produced a concentration-dependent decrease in HIV-1 infectivity. Furthermore, when used in combination the prodrugs show a decrease in infectivity (Figure 1) that suggests an interaction which is more than additive, indicating that the combined antiretroviral effect is similar to what was observed with the parent compounds [4]. Furthermore, the decrease in infectivity did not correlate with a corresponding decrease in cell proliferation (Figure 1) as determined by cellular ATP levels. The concentration of gemcitabine divalerate needed to inhibit proliferation by 50% (IC50) was greater than 5 μM, whereas decitabine divalerate showed less than 5% decrease in cell proliferation at 5 μM (data not shown). Since previous studies have shown that ATP levels are sensitive to both cytotoxic and cytotstatic compounds [35], these results indicate that the prodrugs are neither cytotoxic nor cytotstatic.

Discussion

Drug-resistant HIV-1 is a significant public health problem that emphasizes the need for the development of new anti-HIV-1 therapies that exploit new drug targets. Although the mutation rate has been proposed as a rational drug target, no compounds that lethally mutagenize HIV-1 have been approved for clinical use. We previously described two nucleoside analogues, decitabine and gemcitabine that, when used in combination, decrease HIV-1 replication through lethal mutagenesis. Decitabine and gemcitabine are clinically approved to treat MDS [36,37] and various solid cancers, respectively [38]. In addition to their anti-MDS, anti-cancer, and anti-HIV-1 activities, decitabine and gemcitabine have been shown to have antiviral activity against other retroviruses including feline leukaemia virus [39] and murine leukaemia virus [12,40]. Additionally, gemcitabine exerts antiviral activity against influenza A [41], a member of Orthomyxoviridae. The antiviral activities of decitabine and gemcitabine warrant further investigation into the potential to reposition these drugs as antiviral drugs. However, due to their low intestinal permeability, deamination by cytidine deaminase, and rapid phosphorylation in the liver and kidneys, decitabine and gemcitabine have poor bioavailability and must be administered intravenously. Since repeated administration is not feasible, we used a prodrug approach to increase the intestinal permeability of decitabine and gemcitabine.

Prodrug approaches have been used to increase the bioavailability of several approved nucleoside analogues including tenofovir disoproxil fumarate, valacyclovir, adefovir and famciclovir. In general, prodrug approaches are used to increase intestinal absorption and to enhance drug transport into cells. Here, we describe the divalerate prodrug of decitabine and gemcitabine. The valerate moieties were selected to serve multiple purposes. First, the lipophilicity of

<table>
<thead>
<tr>
<th>Compound</th>
<th>Permeability, 10^-6 cm/s</th>
<th>Percentage recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gemcitabine divalerate</td>
<td>3.2</td>
<td>16</td>
</tr>
<tr>
<td>Decitabine divalerate</td>
<td>2.1</td>
<td>18</td>
</tr>
</tbody>
</table>

Table 1. Permeability and recovery of decitabine, gemcitabine and the divalerate prodrugs of decitabine and gemcitabine

©2014 International Medical Press
the valerate moieties should increase intestinal permeability, which should correlate with an increase in bioavailability. Second, the valerate moiety on the 5′-hydroxyl group should delay phosphorylation in the liver which should improve its tissue distribution. Third, the ester cytosine prodrugs are reported to be resistant to deamination which should improve the ability to attain physiologically relevant concentrations by oral administration [42]. Finally, the valerate moieties should be readily hydrolysed by carboxylesterases that are ubiquitously expressed [43,44]. Abundant expression of carboxylesterase in the liver would be expected to hydrolyse the valerate prodrugs during first pass metabolism [45]. Hydrolysis of the prodrugs releases the free nucleosides, which must then be phosphorylated by cellular kinases in order to become biologically active.

This study has found that decitabine valerate and gemcitabine valerate have increased intestinal permeability when compared to the parent compounds (Table 1), which typically correlates with an increase in bioavailability. The half-life data predicts prodrug stability in the acidic environment of the gastrointestinal tract. Furthermore, both prodrugs demonstrated potent anti-HIV-1 activity at concentrations that were not cytostatic or cytotoxic. To exert antiviral activity, the prodrugs must be hydrolysed to release the parent nucleoside, and this hydrolysis step is dependent on adequate expression of carboxylesterase-1, which is abundantly expressed in the liver on first pass metabolism [45]. Since the prodrugs are expected to be hydrolysed by the liver, the target cells are not expected to play a significant role in the generation of the active drug. Therefore, comparing the antiviral activity of the prodrug to the parent drug in an in vivo system is unlikely to reveal relevant in vivo information.

The increase in prodrug stability and permeability compared to the parent compounds suggest that decitabine valerate and gemcitabine valerate are likely to show improved bioavailability and pharmacokinetic properties while maintaining biological activity. Further studies are warranted to examine the bioavailability of decitabine valerate and gemcitabine valerate in an in vivo system.

Table 2. The half-life of decitabine valerate and gemcitabine valerate at pH 2.0, 4.65 and 7.4

<table>
<thead>
<tr>
<th>Compound</th>
<th>Half-life at pH 2.0, h</th>
<th>Half-life at pH 4.65, h</th>
<th>Half-life at pH 7.4, h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decitabine valerate</td>
<td>17</td>
<td>36</td>
<td>28</td>
</tr>
<tr>
<td>Gemcitabine valerate</td>
<td>85</td>
<td>247</td>
<td>135</td>
</tr>
</tbody>
</table>

Acknowledgements

This research was supported by NIH grant R01 GM56615 and a University of Minnesota Academic Health Center Translational Research Grant.

Disclosure statement

The authors declare no competing interests.

References

43. Imai T, Ohura K. The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr Drug Metab 2010; 11;793–805.